Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Citius Oncology Inc. (CTOR:NASDAQ), powered by AI.
Citius Oncology Inc. is currently trading at $0.66. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Citius Oncology Inc. on Alpha Lenz.
Citius Oncology Inc.'s P/E ratio is -2.0.
“Citius Oncology Inc. trades at a P/E of -2.0 (undervalued) with modest ROE of -54.4%.”
Ask for details →Citius Oncology Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment. The primary function of Citius Oncology is to research and develop innovative therapies that aim to enhance the efficacy and safety profiles of current cancer treatments. The company focuses on leveraging new technology platforms and scientific advancements to address unmet medical needs in various types of cancer, impacting both the oncology and pharmaceutical sectors. Citius Oncology's significance in the market revolves around its commitment to advancing cancer therapeutics, which is a critical area due to the disease's widespread impact globally. As a clinical-stage entity, the company plays a crucial role in the pipeline of medical innovation, contributing to potential future options for cancer care. Citius Oncology partners with research institutions and other biopharmaceutical enterprises to push the boundaries of standard oncology treatments. This makes it an influential player in the biotechnology and healthcare sectors, aligning with a broader industry goal to improve patient outcomes in oncology.
“Citius Oncology Inc. trades at a P/E of -2.0 (undervalued) with modest ROE of -54.4%.”
Ask for details →Citius Oncology Inc. (ticker: CTOR) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $49M.
The current price is $0.664 with a P/E ratio of -1.96x and P/B of 1.08x.
ROE is -54.42%.